Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome

Haüser, Winfried; Urrútia, Gerard; Tort, Sera; Üçeyler, Nurcan; Walitt, Brian

doi:10.1002/14651858.cd010292

Cited by 114 publications

(92 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 Moreover, the acupuncture treatment described in this study was associated with a lower rate of adverse effects than drug treatments used in clinical practice.…”

Section: Comparison With Previous Studies Of Pharmacological Treatmentmentioning

confidence: 74%

Acupuncture for Fibromyalgia in Primary Care: A Randomised Controlled Trial

Vas¹,

Santos-Rey²,

Navarro-Pablo

et al. 2016

Acupunct Med

View full text Add to dashboard Cite

Objectives To evaluate the efficacy of an individualised acupuncture protocol for patients with fibromyalgia. Methods Randomised controlled multicentre trial, blinded to participants and to data analysts. Conducted in three primary care centres in southern Spain. A total of 164 participants aged over 17 years and diagnosed with fibromyalgia were enrolled in this trial; 153 participants completed the study. Participants were randomly assigned to either the real intervention (individualised acupuncture, IA) or the sham intervention (sham acupuncture, SA). In both the IA and SA groups, one session per week (lasting 20 min) was provided, in addition to usual pharmacological treatment. The primary outcome was change in pain intensity at 10 weeks. Results Intention-to-treat analysis revealed that the decrease in pain intensity at 10 weeks was greater (p=0.001) in the IA group (−41.0%, 95% CI −47.2% to −34.8%) than in the SA group (−27.1%, 95% CI −33.2% to −20.9%). During the follow-up period, significant differences (p<0.01) in favour of the IA group persisted at 12 months (IA: −19.9%, 95% CI −24.6% to −15.1%; vs SA: −6.2%, 95% CI −11.2% to −1.2%). Conclusions Individualised acupuncture treatment in primary care in patients with fibromyalgia proved efficacious in terms of pain relief, compared with placebo treatment. The effect persisted at 1 year, and its side effects were mild and infrequent. Therefore, the use of individualised acupuncture in patients with fibromyalgia is recommended. Trial Registration Number ISRCTN60217348.

show abstract

“…40 Moreover, the acupuncture treatment described in this study was associated with a lower rate of adverse effects than drug treatments used in clinical practice.…”

Section: Comparison With Previous Studies Of Pharmacological Treatmentmentioning

confidence: 74%

Acupuncture for Fibromyalgia in Primary Care: A Randomised Controlled Trial

Vas¹,

Santos-Rey²,

Navarro-Pablo

et al. 2016

Acupunct Med

View full text Add to dashboard Cite

show abstract

“…The regulation of pain in FMS via drug interventional studies designed to inhibit selective serotonin (SSRI) or serotonin/noradrenaline-norepinephrine (SNRI) reuptake has also resulted in the development of paroxetine, duloxetine and milnaciprin, respectively for the treatment of FMS [31]. However, despite these developments in identifying novel drug targets based on pharmacotherapeutic interventions for FMS [32], a recent analysis indicated that FMS essentially remains without effective treatments as indicated by the fact that clinical trials with tricyclic antidepressants, SSRIs, opioids, gabapentin [33] or SNRIs [34] have all produced mixed clinical efficacy results.…”

Section: Updating the Pain Pathways Relevant To Fibromyalgia: Do Theymentioning

confidence: 99%

Recent strategies for drug development in fibromyalgia syndrome

Blumenthal

Malemud

2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

The US Federal Drug Administration (FDA) approved 3 medications for treating fibromyalgia syndrome (FMS). There have been no additional FDA approvals since January 2009 and the efficacy of the FDA-approved medications for FMS has been questioned. Areas covered: The "search for studies" tool using clinicaltrials.gov and PubMed were employed. The term, "fibromyalgia" was used for clinicaltrials.gov. The terms employed for PubMed were "Name-of-Drug Fibromyalgia", "Fibromyalgia Treatment" or "Fibromyalgia Drug Treatment." Clinical trials were reviewed if they were prospective and blinded, and if they employed a comparator, either placebo or another pharmaceutical. Expert commentary: Progress toward standardizing the outcome measures for FMS clinical trials have been made but challenges remain. Several pharmaceutical candidates for FMS have been tested since 2009. The results of these studies with potential novel targets for drug development for FMS were reviewed including the results of trials with sodium oxybate, quetiapine, esreboxetine, nabilone, memantine, naltrexone, and melatonin.

show abstract

“…Developing and coordinating evidence-based national guidelines on topics relevant to psychosomatic medicine, such as functional/somatoform or eating disorders, has been an important undertaking in recent years [22,40,41,42,43,44]. Researchers of psychosomatic medicine have also participated in several population-based cohorts in Germany (e.g.…”

Section: Psychosomatic Medicine In Academic Teaching and Researchmentioning

confidence: 99%